Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multicenter, single-arm, phase 2 trial. The aim of this study is to evaluate the efficacy and safety of herombopag combined with cyclosporine for patients with non severe aplastic anemia (NSAA).

Detailed Description
-----------------
This study aims to improve the 24 weeks response rate. The sample size is calculated based on Simon's two-stage design. The first stage of the study enrolled a cohort of 15 patients. If after 24 weeks at least 9 patients achieved a response, then enrollment was expanded to a total of 43 patients. The null hypothesis was unaccepted if more than 26 of 43 patients achieved the response. Accounting for a 20% dropout rate, the estimated final sample size was 54 patients.

Official Title
-----------------
The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia

Conditions
-----------------
Non Severe Aplastic Anemia, Untreated

Intervention / Treatment
-----------------
* Drug: Herombopag


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to comply with the requirements for this study and written informed consent. Male or female age ≥ 18 years Diagnosis of untreated non severe aplastic anemia. Platelet counts < 50 x 10^9/L at least 2 times consecutively (time interval ≥ 1 week) Exclusion Criteria: Receive immunosuppressive therapy more than 4 weeks before enrollment Treatment with TPO-RA within 1 week before enrollment Inherited bone marrow failure syndromes Bone marrow fibrosis grade ≥ 2 The presence of hemolytic PNH clone The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category) Previously treated with TPO-RA ≥ 4 weeks Previously received immunosuppressive therapy ≥ 12 weeks Ferritin > 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category) Have an allergy to eltrombopag or any other part of this medicine. History of radiotherapy and chemotherapy for malignant solid tumors Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc Abnormal liver function: ALT or AST > 3 ULN, or TBil > 1.5 ULN after treatment. Abnormal kidney function: Creatinine clearance < 30 ml/min, or serum creatinine (sCr) >1.5 ULN Patients with diabetic nephropathy, neuropathy, or eye disease Patients with poorly controlled hypertension or cardiac arrhythmia Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF < 45% within 4 weeks before enrollment History of arteriovenous thrombosis within 1 year before enrollment Participation in another clinical trial within 4 months before the start of this trial Pregnant or breast-feeding patients Patients considered to be ineligible for the study by the investigator for reasons other than the above

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CsA + Herombopag<br>Herombopag combined with cyclosporine | Drug: Herombopag<br>* Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT. Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.<br>* Other names: Cyclosporine A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate | Percentage of patients with hematological response. Hematological response is evaluated by hemoglobin, platelet and neutrophil count in the routine blood test. | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Robust response rate | Percentage of patients with robust response, including complete response, near complete response, very good partial response(VGPR) and Meaningful partial response(mPR). These are evaluated by hemoglobin, platelet and neutrophil count in the routine blood test. | 24 weeks | 
| Proportion of patients with abnormal karyotype changes | The abnormal karyotype was examined by karyotype test | Baseline and 24 weeks | 
| Time duration for patients achieving hematological response | Duration time was calculated from response to relapse. | A minimum of 2 years of planned follow-up | 
| Change of the health-related quality of life | Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is used to assess the health-related quality of life of patients. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100. Lower scores = more disability, higher scores = less disability | Baseline and 24 weeks | 
| Incidence of the adverse event | Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event. | 24 weeks | 
| Severity of the adverse event | Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the severity. | 24 weeks |